- Home
- ARR vs ALMR Comparison
ARR vs ALMR Comparison
Compare ARR & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | ALMR |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2009 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ARR | ALMR |
|---|---|---|
| Price | $15.14 | $28.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 261.2K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | ★ 747.06 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.98 | $21.58 |
| 52 Week High | $19.31 | $38.54 |
Technical Indicators
Market Signals| Indicator | ARR | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 41.84 |
| Support Level | $15.32 | $23.69 |
| Resistance Level | $17.72 | $28.35 |
| Average True Range (ATR) | 0.24 | 1.94 |
| MACD | -0.06 | -0.69 |
| Stochastic Oscillator | 2.84 | 9.57 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About ALMR Alamar Biosciences Inc. Common Stock
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.